DoW, Peer Reviewed Cancer, Impact Award
DoW, Peer Reviewed Cancer, Impact Award is a published development and funding opportunity on Contexium. The donor or funder is Defense Health Agency Contracting Activity - DHACA. Project location(s): United States. Applications close on 05 Oct 2026. Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lea…
Opportunity overview
- Project name
- DoW, Peer Reviewed Cancer, Impact Award
- Donor
- Defense Health Agency Contracting Activity - DHACA
Key details
- Opportunity start date
- Opportunity end date
- Project location(s)
- United States
Summary
Frequently asked questions
What is DoW, Peer Reviewed Cancer, Impact Award?
DoW, Peer Reviewed Cancer, Impact Award is a published development and funding opportunity on Contexium. The donor or funder is Defense Health Agency Contracting Activity - DHACA. Project location(s): United States. Applications close on 05 Oct 2026. Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lea…
Who is funding DoW, Peer Reviewed Cancer, Impact Award?
DoW, Peer Reviewed Cancer, Impact Award is funded by Defense Health Agency Contracting Activity - DHACA.
When is the deadline to apply for DoW, Peer Reviewed Cancer, Impact Award?
The application deadline is 05 Oct 2026 00:00 (UTC).
Where will the DoW, Peer Reviewed Cancer, Impact Award project take place?
The project location(s) are: United States.
How can I apply for DoW, Peer Reviewed Cancer, Impact Award?
Create a free Contexium account to view the full opportunity details and submit an application via the marketplace.